Literature DB >> 31962751

Randomized phase 1b/3 study of erlotinib plus ramucirumab in first-line EGFR mut + stage IV NSCLC: phase 1b safety results.

K Nakagawa1, E B Garon2, L Paz-Ares3, S Ponce3, J Corral Jaime4, O Juan Vidal5, E Nadal6, K Kiura7, S He8, J Treat8, R Dalal9, P Lee10, M Reck11, S Novello12.   

Abstract

Year:  2017        PMID： 31962751     DOI： 10.1093/annonc/mdx426.005

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  1 in total

1.  Blood mRNA expression of REV3L and TYMS as potential predictive biomarkers from platinum-based chemotherapy plus pemetrexed in non-small cell lung cancer patients.

Authors:  M Teresa Agulló-Ortuño; Inmaculada García-Ruiz; C Vanesa Díaz-García; Ana B Enguita; Virginia Pardo-Marqués; Elena Prieto-García; Santiago Ponce; Lara Iglesias; Jon Zugazagoitia; José A López-Martín; Luis Paz-Ares; Juan A Nuñez
Journal:  Cancer Chemother Pharmacol       Date:  2019-12-12       Impact factor: 3.333
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.